Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01642732 · ClinicalTrials.gov registry record · Phase 1
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01642732 is a Phase 1 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT01642732, a Phase 1 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purposes of this study are to: * Determine the safest and highest dose of the study drug RAD001 (Everolimus) that can be taken in combination with hormonal and radiation therapy in men with high risk prostate cancer. * Evaluate changes in patient reported quality of life * Evaluate biomarkers from prostate tumor samples. Biomarkers are various traits which can be used to identify the progress of a disease or condition, which can help researchers determine the effect the study treatment has on the tumor. Biomarkers can also help determine areas for further research.
Interventions
- OTHER Everolimus, lupron, bicalutamide, and radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01642732
The ClinicalTrials.gov registry entry for NCT01642732 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus, lupron, bicalutamide, and radiation is the first listed.
NCT01642732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01642732 about?
NCT01642732 is a clinical study titled "Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer". The purposes of this study are to: * Determine the safest and highest dose of the study drug RAD001 (Everolimus) that can be taken in combination with hormonal and radiation therapy in men with high risk prostate cancer. * Evaluate changes in patient reported quality of life * Evaluate biomarkers f...
What is the current status of trial NCT01642732?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01642732?
The interventions under investigation include: Everolimus, lupron, bicalutamide, and radiation (OTHER).
Who is sponsoring clinical trial NCT01642732?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.